New York, USA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Sickle Cell Disease Clinical Trial Pipeline Gains Momentum: 45+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

The sickle cell disease clinical trial analysis report delivers important insights into ongoing research of 50+ pipeline sickle cell disease drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

DelveInsight’s 'Sickle Cell Disease Pipeline Insight 2026' report provides comprehensive global coverage of pipeline therapies for sickle cell disease across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the sickle cell disease domain.

Sickle Cell Disease Clinical Trial Analysis Summary

• DelveInsight’s sickle cell disease pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline sickle cell disease drugs. 
• Key sickle cell disease companies, such as Novo Nordisk, Biossil Inc., Kamau Therapeutics, Novartis, CorrectSequence Therapeutics, CorrectSequence Therapeutics, Disc Medicine, Inc., CSL Behring, Sanofi, Bristol-Myers Squibb, Beam Therapeutics Inc., MiNA Therapeutics, Ensoma, Inc., Reforgene Medicine, YolTech, Incisive Genetics, GluBio Therapeutics, Enlaza Therapeutics, Vertex Pharmaceuticals, and others, are evaluating new sickle cell disease drugs to improve the treatment landscape.
• Promising pipeline sickle cell disease therapies, such as Etavopivat, SIL-8301, Nulabeglogene autogedtemcel, ITU512, CS-206, DISC-3405, CSL324, Rilzabrutinib, BMS-986470, BEAM-101, MTL-HBG, Research Program, RM001, YOLT-204, IG-SCD 1, GLB-005, Research Program: Drug Conjugates, and others, are in different phases of sickle cell disease clinical trials.
• Approximately 5+ sickle cell disease drugs are in the late stages of development.
• Notable MoAs in sickle cell disease clinical trials include PK Activator, Gardos channel (KCNN4) inhibitor, cell replacement, Fetal haemoglobin expression stimulants, Gene transference, TMPRSS6 protein inhibitors, EED protein inhibitors, Increases fetal hemoglobin (HbF), and others.

Request a sample and discover the recent advances in sickle cell disease treatment @ https://www.delveinsight.com/report-store/sickle-cell-disease-pipeline-insight

What is Sickle Cell Disease?

Sickle cell disease (SCD) is a group of inherited blood disorders caused by mutations in the HBB gene, which leads to the production of abnormal hemoglobin known as hemoglobin S. This causes red blood cells to become rigid and adopt a characteristic sickle or crescent shape, particularly under conditions of low oxygen. Unlike normal red blood cells, which are flexible and survive for about 120 days, sickled cells can break down prematurely, resulting in chronic hemolytic anemia, and may obstruct small blood vessels, causing painful vaso-occlusive crises and tissue damage. SCD can also lead to complications such as acute chest syndrome, stroke, infections, kidney dysfunction, and progressive organ damage. The disease is inherited in an autosomal recessive manner and includes several genotypes, with HbSS and HbSβ⁰-thalassemia generally associated with more severe disease.

Find out more about gene therapy for sickle cell disease @ Sickle Cell Disease New Treatment

A snapshot of the Pipeline Sickle Cell Disease Drugs mentioned in the report:

Learn more about the sickle cell disease research companies @ Sickle Cell Disease Clinical Trials 

Stuti Mahajan, Functional Head of Consulting at DelveInsight, said that the sickle cell disease market is expected to shift toward more targeted and disease-modifying therapies, supported by the advancement of oral metabolic therapies, gene therapies, and fetal hemoglobin–inducing approaches. Positive Phase III data for etavopivat and the regulatory progress of mitapivat could expand pharmacological treatment options, while programs such as BEAM-101 and CS-206 may drive longer-term disease modification. Growing investment in novel mechanisms, including G9a inhibition, TMPRSS6 inhibition, hemopexin replacement, and anti-inflammatory approaches, is expected to further diversify the pipeline. Overall, the market outlook remains innovation-driven, with increasing emphasis on reducing VOCs, improving hemoglobin levels, and achieving durable treatment responses.

Recent Developments in Sickle Cell Disease Treatment Space

• In July 2026, Agios Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for mitapivat, an oral pyruvate kinase (PK) activator, in sickle cell disease with a Priority Review. The Prescription Drug User Fee Act (PDUFA) goal date for this sNDA, submitted under the FDA’s accelerated approval pathway, is November 1, 2026.
• In June 2026, CorrectSequence Therapeutics Co., Ltd. announced that the first sickle cell disease (SCD) patient being treated in China with its high-precision base-editing therapy CS-206 has remained free of vaso-occlusive crises (VOCs) for more than 15 months following engraftment. Starting from 60 Days after the last red-cell transfusion, the patient has remained free from VOCs and anemia for 13 consecutive months, achieving the primary efficacy endpoint. The follow-up data demonstrated favorable safety and efficacy of CS-206.
• In April 2026, Novo Nordisk announced the topline results from HIBISCUS, a pivotal phase III trial of once-daily oral etavopivat in adults and adolescents with sickle cell disease (SCD). The results showed that etavopivat successfully met both co-primary endpoints, demonstrating superior reduction in vaso-occlusive crises (VOCs) and superior improvement in haemoglobin (Hb) response compared to placebo.
• In March 2026, EpiFrontier Therapeutics, Inc., a biotechnology company developing transformative therapies for beta globin disorders, announced its award of up to USD 32 million in non-dilutive funding from the Japan Agency for Medical Research and Development (AMED). The grant will advance the clinical development of EPF-001, a novel small molecule G9a inhibitor designed to increase fetal hemoglobin expression in patients with sickle cell disease and beta thalassemia.
• In September 2025, Enlaza Therapeutics, the first covalent biologics platform company, announced a multi-target drug discovery collaboration with Vertex Pharmaceuticals to utilize Enlaza’s proprietary War-Lock™ technology platform to develop small format drug conjugates and T-cell engagers for certain autoimmune diseases and improved conditioning in sickle cell disease and beta thalassemia.
• In August 2025, Beam Therapeutics Inc. announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD)
• In June 2025, the US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, a novel, advanced, oral, reversible Bruton's tyrosine kinase (BTK) inhibitor that works via multi-immune modulation, to target a reduction in vaso-occlusive crises, which may occur via inflammation, in sickle cell disease.
• In June 2025, Beam Therapeutics Inc. announced that the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD).

Scope of the Sickle Cell Disease Pipeline Report 

• Coverage: Global 
• Sickle Cell Disease Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Sickle Cell Disease Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Sickle Cell Disease Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Oral, Parenteral, Subcutaneous, Topical, Transdermal
• Sickle Cell Disease Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
• Sickle Cell Disease Therapeutics Assessment By Mechanism of Action: PK Activator, Gardos channel (KCNN4) inhibitor, cell replacement, Fetal haemoglobin expression stimulants, Gene transference, TMPRSS6 protein inhibitors, EED protein inhibitors, Increases fetal hemoglobin (HbF), and others
• Key Sickle Cell Disease Companies: Novo Nordisk, Biossil Inc., Kamau Therapeutics, Novartis, CorrectSequence Therapeutics, Disc Medicine, Inc., CSL Behring, Sanofi, Bristol-Myers Squibb, Beam Therapeutics Inc., MiNA Therapeutics, Ensoma, Inc., Reforgene Medicine, YolTech, Incisive Genetics, GluBio Therapeutics, Enlaza Therapeutics, Vertex Pharmaceuticals, and others.
• Key Sickle Cell Disease Pipeline Therapies: Etavopivat, SIL-8301, Nulabeglogene autogedtemcel, ITU512, CS-206, DISC-3405, CSL324, Rilzabrutinib, BMS-986470, BEAM-101, MTL-HBG, Research Program, RM001, YOLT-204, IG-SCD 1, GLB-005, Research Program: Drug Conjugates, and others.

Dive deep into rich insights for sickle cell disease cure, visit @ Sickle Cell Disease News

Table of Contents

For further information on the sickle cell disease clinical trials, reach out @ Sickle Cell Disease Medication

Related Reports

Sickle Cell Disease Market

Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SCD companies, including Pfizer, Agios Pharmaceuticals, Fulcrum Therapeutics, Novo Nordisk, Scribe Therapeutics, Sanofi, and others.

Hemophilia Market

Hemophilia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hemophilia companies, including Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk, and others.

Hemophilia A Market

Hemophilia A Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hemophilia A companies, including Novo Nordisk, Ultragenyx Pharmaceutical, Sangamo Therapeutics, ASC Therapeutics, Roche, Chugai, Sanofi, Alnylam Pharmaceuticals, Pfizer, Genentech, BioMarin Pharmaceutical, HEMA Biologics, LFB Pharmaceuticals, Octapharma, CSL Behring, Octapharma, Bayer, Takeda, and others.

Hemophilia B Market

Hemophilia B Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hemophilia B companies, including UniQure Biopharma B.V., CSL Behring, Pfizer, Spark Therapeutics, Genzyme, a Sanofi Company, Alnylam Pharmaceuticals, Novo Nordisk, UniQure Biopharma B.V., ApcinteX Ltd, Freeline Therapeutics, Sangamo Therapeutics, and others.

Thalassemia Market

Thalassemia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key thalassemia companies, including Novo Nordisk A/S, CorrectSequence Therapeutics Co., Ltd, Shanghai BDgene Co., Ltd., Bioray Laboratories, Mabwell (Shanghai) Bioscience Co., Ltd., Lantu Biopharma, Kind Pharmaceuticals LLC, Kanglin Biotechnology (Hangzhou) Co., Ltd., Pharmacosmos A/S, Regeneron Pharmaceuticals, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679